MedTrace Logo

Tiotropium Efficacy Against Allergen Induced Early Asthmatic Responses

NCT04648813 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2021-09-30

No results posted yet for this study

Summary

The study will compare the effect of inhaled tiotropium versus placebo on allergen induced early asthmatic responses in individuals with atopic asthma.

Conditions

  • Allergic Asthma

Interventions

DRUG

tiotropium bromide monohydrate (Spiriva Respimat)

administered daily, 2 inhalations/5mcg per dose for a total of 8 doses

DRUG

matching placebo

administered daily, 2 inhalations per dose for a total of 8 doses

Sponsors & Collaborators

  • University of Saskatchewan

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-13
Primary Completion
2021-04-20
Completion
2021-04-20

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04648813 on ClinicalTrials.gov